The US company, a major maker of insulin and diabetes products, says its ‘Brexit investment has been significant and in many cases our planning, including our own medicines stockpiling, exceeds government guidance’.

Lilly’s Erl Wood Research Centre in Windlesham is its global centre of excellence for neuroscience research.

The US company, a major maker of insulin and diabetes products, says its ‘Brexit investment has been significant and in many cases our planning, including our own medicines stockpiling, exceeds government guidance’.

Lilly’s Erl Wood Research Centre in Windlesham is its global centre of excellence for neuroscience research.